Aura Biosciences reports Q2 EPS (48c), consensus (49c)

As of June 30, Aura had cash and cash equivalents and marketable securities totaling $162M. Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the second half of 2025. “As we build momentum across our portfolio, we are happy to welcome Drs. Bruce Brown and Anthony Daniels as our Therapeutic Area Heads in Urologic Oncology and Ocular Oncology, respectively, as well as Dr. Richard Mountfield as our new Senior Vice President of Regulatory Affairs and Quality. These key appointments are critical in supporting our corporate growth and expansion of our clinical programs in two important oncology therapeutic areas with high unmet medical needs for patients,” said Elisabet de los Pinos, CEO of Aura.